Clinical trial of three-month TB treatment regimen closed due to high rate of unfavorable outcomes

FHS
July 5, 2023
4:22 pm

The first clinical trial of a three-month tuberculosis (TB) treatment regimen is closing enrollment because of a high rate of unfavorable outcomes with the investigational course of treatment.

A novel biomonitoring method reveals neurotoxic chemical mixtures in human blood

Studies of chemicals in our blood typically capture only a small and unknown fraction of the entire chemical universe. Now, a new approach aims to

October 18, 2024

Long-Acting Injection Preferred Over Daily Pills for PrEP

BRISBANE, Australia – When given a choice for pre-exposure prophylaxis (PrEP) to prevent infection with HIV, women preferred injectable cabotegravir (Apretude) every 2 months rather

July 21, 2023

Dispute over Duchenne gene therapy highlights thorny access issues

Finally, it seemed, Sarah Jenssen would have a chance to get a treatment that her family hoped could help her. A gene therapy for Sarah’s

September 27, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.